Catalogue Search | MBRL
Search Results Heading
Explore the vast range of titles available.
MBRLSearchResults
-
DisciplineDiscipline
-
Is Peer ReviewedIs Peer Reviewed
-
Series TitleSeries Title
-
Reading LevelReading Level
-
YearFrom:-To:
-
More FiltersMore FiltersContent TypeItem TypeIs Full-Text AvailableSubjectCountry Of PublicationPublisherSourceTarget AudienceDonorLanguagePlace of PublicationContributorsLocation
Done
Filters
Reset
196,505
result(s) for
"Spinal"
Sort by:
Neuroscience : exploring the brain
\"Surveys the organization and function of the human nervous system ... in a way that is accessible to both science and nonscience students alike. The level of the material is comparable to an introductory college text in general biology. The book is divided into four parts: Part I, Foundations; Part II, Sensory and motor systems; Part III, The brain and behavior; and Part IV, The changing brain\"--Provided by publisher.
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
by
Zhong, Z. John
,
Chiriboga, Claudia A
,
Saito, Kayoko
in
Age of Onset
,
Antisense oligonucleotides
,
Babies
2017
In this phase 3 trial, among infants with spinal muscular atrophy, those who received nusinersen were more likely to achieve major motor milestones and less likely to need permanent assisted ventilation than those who underwent a sham procedure.
Journal Article
Spinal Cord Injury
by
Injury, Committee on Spinal Cord
,
Health, Board on Neuroscience and Behavioral
,
Medicine, Institute of
in
Spinal cord
,
Spinal cord-Wounds and injuries
,
Spinal cord-Wounds and injuries-Research-United States
2005
An estimated 11,000 spinal cord injuries occur each year in the United
States and more than 200,000 Americans suffer from maladies associated
with spinal cord injury. This includes paralysis, bowel and bladder dysfunction,
sexual dysfunction, respiratory impairment, temperature regulation
problems, and chronic pain. During the last two decades, longstanding
beliefs about the inability of the adult central nervous system to heal itself
have been eroded by the flood of new information from research in the
neurosciences and related fields. However, there are still no cures and the
challenge of restoring function in the wake of spinal cord injuries remains
extremely complex.
Spinal Cord Injury examines the future directions for research with the
goal to accelerate the development of cures for spinal cord injuries. While
many of the recommendations are framed within the context of the specific
needs articulated by the New York Spinal Cord Injury Research Board,
the Institute of Medicine's panel of experts looked very broadly at research
priorities relating to future directions for the field in general and make recommendations
to strengthen and coordinate the existing infrastructure.
Funders at federal and state agencies, academic organizations, pharmaceutical
and device companies, and non-profit organizations will all find this
book to be an essential resource as they examine their opportunities.
The China-US partnership to prevent spina bifida : the evolution of a landmark epidemiological study
\"An American-Chinese partnership to prevent spina bifida and related birth defects succeeded through old-fashioned field epidemiology, advocates with influence, and genuine collaboration based on personal relationships built on trust, respect, and shared proboblem-solving\"--Provided by publisher.
Improvement in Motor and Walking Capacity during Multisegmental Transcutaneous Spinal Stimulation in Individuals with Incomplete Spinal Cord Injury
2024
Transcutaneous multisegmental spinal cord stimulation (tSCS) has shown superior efficacy in modulating spinal locomotor circuits compared to single-site stimulation in individuals with spinal cord injury (SCI). Building on these findings, we hypothesized that administering a single session of tSCS at multiple spinal segments may yield greater enhancements in muscle strength and gait function during stimulation compared to tSCS at only one or two segments. In our study, tSCS was applied at single segments (C5, L1, and Coc1), two segments (C5-L1, C5-Coc1, and L1-Coc1), or multisegments (C5-L1-Coc1) in a randomized order. We evaluated the 6-m walking test (6MWT) and maximum voluntary contraction (MVC) and assessed the Hmax/Mmax ratio during stimulation in ten individuals with incomplete motor SCI. Our findings indicate that multisegmental tSCS improved walking time and reduced spinal cord excitability, as measured by the Hmax/Mmax ratio, similar to some single or two-site tSCS interventions. However, only multisegmental tSCS resulted in increased tibialis anterior (TA) muscle strength. These results suggest that multisegmental tSCS holds promise for enhancing walking capacity, increasing muscle strength, and altering spinal cord excitability in individuals with incomplete SCI.
Journal Article
Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial
by
Tauscher-Wisniewski, Sitra
,
Zaidman, Craig M.
,
Strauss, Kevin A.
in
631/208/135
,
631/208/2489/201
,
Atrophy
2022
SPR1NT (
NCT03505099
) was a Phase III, multicenter, single-arm study to investigate the efficacy and safety of onasemnogene abeparvovec for presymptomatic children with biallelic
SMN1
mutations treated at ≤6 weeks of life. Here, we report final results for 14 children with two copies of
SMN2
, expected to develop spinal muscular atrophy (SMA) type 1. Efficacy was compared with a matched Pediatric Neuromuscular Clinical Research natural-history cohort (
n
= 23). All 14 enrolled infants sat independently for ≥30 seconds at any visit ≤18 months (Bayley-III item #26;
P
< 0.001; 11 within the normal developmental window). All survived without permanent ventilation at 14 months as per protocol; 13 maintained body weight (≥3rd WHO percentile) through 18 months. No child used nutritional or respiratory support. No serious adverse events were considered related to treatment by the investigator. Onasemnogene abeparvovec was effective and well-tolerated for children expected to develop SMA type 1, highlighting the urgency for universal newborn screening.
For presymptomatic infants at risk for SMA type 1, onasemnogene abeparvovec improves motor outcomes, ventilator-free survival, and nutritional/respiratory independence compared with untreated or treated symptomatic patients
Journal Article
Hazel has her hands full
by
Fairbairn, Nathan, author
,
Msassyk, illustrator
in
Graphic novels.
,
Friendship Fiction.
,
Dog walking Fiction.
2025
\"The PAWS girls face a busy summer season full of dog-walking, travel, and fun, while Hazel takes on a big challenge\"-- Provided by publisher.
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy
by
Chiriboga, Claudia A
,
Foster, Richard
,
Day, John W
in
Age of Onset
,
Antisense oligonucleotides
,
backache
2018
In this phase 3 trial, among children with later-onset spinal muscular atrophy, those who received nusinersen had improvement in motor-function scores and those who underwent a sham procedure did not.
Journal Article